Business
ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2024
PORTLAND, Maine, Feb. 25, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter and year ended December 31, 2024. Product Sales Highlights: Fourth quarter of 2024 product sales increased 52% to approximately $7.8 m
About this update from Immucell Corporation
[{"type":"image","alt":"ImmuCell Corporation","displaySize":"","headline":null,"caption":"ImmuCell Corporation","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":36,"url":"https://media.zenfs.com/en/globenewswire.com/444055d59bf7cb6f681f3be8a2dd02bc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7ckduXNsI_qLHBNY2yY.og--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTUwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/444055d59bf7cb6f681f3be8a2dd02bc","width":300,"height":36}},"lazy":false},{"type":"text","content":"PORTLAND, Maine, Feb. 25, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter and year ended December 31, 2024.","length":409,"tagName":"p"},{"type":"text","content":"Product Sales Highlights:","length":25,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Fourth quarter of 2024 product sales increased 52% to approximately $7.8 million compared to the fourth quarter ended December 31, 2023.","length":136,"tagName":"p"}]},{"val":[{"type":"text","content":"Full year of 2024 product sales increased 52% to approximately $26.5 million compared to the year ended December 31, 2023.","length":122,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":258,"olType":false},{"type":"text","content":"Management’s Discussion:","length":24,"tagName":"p"},{"type":"text","content":"“Our preliminary, unaudited product sales for the fourth quarter and full year of 2024 were first reported on January 9, 2025,” commented Michael F. Brigham, President and CEO of ImmuCell. “We have no changes to those figures.”","length":227,"tagName":"p"},{"type":"text","content":"“We have continued to operate without another contamination event since April of 2024, which leads us to believe that we have effectively remediated the problem and are keeping the bioburden within specification,” continued Mr. Brigham. “We are now focused on improving our production yields and gross margins.”","length":311,"tagName":"p"},{"type":"text","content":"“The significant increase in sales over prior periods demonstrates the beginning of our...